JP2022542670A5 - - Google Patents
Info
- Publication number
- JP2022542670A5 JP2022542670A5 JP2022504629A JP2022504629A JP2022542670A5 JP 2022542670 A5 JP2022542670 A5 JP 2022542670A5 JP 2022504629 A JP2022504629 A JP 2022504629A JP 2022504629 A JP2022504629 A JP 2022504629A JP 2022542670 A5 JP2022542670 A5 JP 2022542670A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- amino acid
- seq
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025145010A JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878977P | 2019-07-26 | 2019-07-26 | |
| US62/878,977 | 2019-07-26 | ||
| PCT/KR2020/009870 WO2021020845A1 (en) | 2019-07-26 | 2020-07-27 | Anti-egfr/anti-4-1bb bispecific antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Division JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542670A JP2022542670A (ja) | 2022-10-06 |
| JP2022542670A5 true JP2022542670A5 (enExample) | 2023-08-03 |
| JP7738545B2 JP7738545B2 (ja) | 2025-09-12 |
Family
ID=74189704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504629A Active JP7738545B2 (ja) | 2019-07-26 | 2020-07-27 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12168690B2 (enExample) |
| EP (1) | EP4004053A4 (enExample) |
| JP (2) | JP7738545B2 (enExample) |
| KR (1) | KR20220038767A (enExample) |
| CN (2) | CN114450306B (enExample) |
| AU (1) | AU2020320349A1 (enExample) |
| BR (1) | BR112022001329A2 (enExample) |
| CA (1) | CA3147420A1 (enExample) |
| MX (1) | MX2022001027A (enExample) |
| WO (1) | WO2021020845A1 (enExample) |
| ZA (1) | ZA202200905B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021008870A2 (pt) | 2019-08-12 | 2021-11-30 | Abl Bio Inc | Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| JP2025512915A (ja) * | 2022-04-07 | 2025-04-22 | ユハン コーポレーション | Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物 |
| EP4644417A4 (en) * | 2022-12-30 | 2026-02-11 | Abclon Inc | AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| KR102927129B1 (ko) | 2025-03-18 | 2026-02-11 | 이트너스 주식회사 | 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0766745T3 (da) | 1995-04-08 | 2002-11-25 | Lg Chemical Ltd | Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
| EP3539981A1 (en) * | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| SG11201601542SA (en) * | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
| CA3138083A1 (en) * | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| EP3356401B1 (en) * | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| JP2019513373A (ja) | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| EP3445788B1 (en) * | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| EP3655439A1 (en) * | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| JP7575100B2 (ja) * | 2018-11-13 | 2024-10-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫細胞活性化のための二重特異性抗体 |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| BR112021008870A2 (pt) * | 2019-08-12 | 2021-11-30 | Abl Bio Inc | Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. |
| JP7702961B6 (ja) * | 2020-02-28 | 2025-07-17 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用 |
-
2020
- 2020-07-27 CN CN202080053851.6A patent/CN114450306B/zh active Active
- 2020-07-27 CN CN202410360186.5A patent/CN118221825A/zh active Pending
- 2020-07-27 JP JP2022504629A patent/JP7738545B2/ja active Active
- 2020-07-27 EP EP20848658.9A patent/EP4004053A4/en active Pending
- 2020-07-27 MX MX2022001027A patent/MX2022001027A/es unknown
- 2020-07-27 BR BR112022001329A patent/BR112022001329A2/pt unknown
- 2020-07-27 US US16/939,472 patent/US12168690B2/en active Active
- 2020-07-27 WO PCT/KR2020/009870 patent/WO2021020845A1/en not_active Ceased
- 2020-07-27 CA CA3147420A patent/CA3147420A1/en active Pending
- 2020-07-27 KR KR1020227006641A patent/KR20220038767A/ko active Pending
- 2020-07-27 AU AU2020320349A patent/AU2020320349A1/en active Pending
-
2022
- 2022-01-19 ZA ZA2022/00905A patent/ZA202200905B/en unknown
-
2024
- 2024-11-04 US US18/935,875 patent/US20250066487A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145010A patent/JP2026004296A/ja active Pending